Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
List view / Grid view
refractory multiple myeloma
Filter the results
Research has shown that the CAR-T therapies in development in Asia-Pacific will make the worldwide market more competitive and drive down prices.